Kawashima Jun, Akabane Miho, Khalil Mujtaba, Woldesenbet Selamawit, Endo Yutaka, Sahara Kota, Cauchy François, Aucejo Federico, Marques Hugo P, Lopes Rita, Rodriguea Andreia, Hugh Tom, Shen Feng, Maithel Shishir K, Groot Koerkamp Bas, Popescu Irinel, Kitago Minoru, Weiss Matthew J, Martel Guillaume, Pulitano Carlo, Aldrighetti Luca, Poultsides George, Ruzzente Andrea, Bauer Todd W, Gleisner Ana, Endo Itaru, Troisi Roberto I, Pawlik Timothy M
Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, Wexner Medical Center and James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Department of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.
Ann Surg Oncol. 2025 Apr 15. doi: 10.1245/s10434-025-17270-4.
The role of anatomic resection (AR) versus non-anatomic resection (NAR) for intrahepatic cholangiocarcinoma (ICC) has not been thoroughly investigated. This study sought to define the impact of tumor size on the relative therapeutic benefit of AR versus NAR for ICC. Specifically, the study aimed to identify a threshold tumor size to define when AR rather than NAR may be warranted to achieve better survival outcomes for patients undergoing resection of ICC.
Patients who underwent liver resection for ICC were identified from an international multi-institutional database. A multivariable Cox model with an interaction term was used to assess the relationship between tumor size and the survival impact of AR.
Among 969 patients, 506 (72.9 %) underwent AR, whereas 263 (27.1 %) had an NAR. Multivariable analysis demonstrated an interaction between tumor size and AR (hazard ratio [HR], 0.94; 95 % confidence interval [CI], 0.88-1.00; p = 0.045). A plot of the interaction demonstrated that AR was associated with improved outcomes for tumors size ≥4 cm. Among 257 (26.5 %) patients with tumors smaller than 4 cm, recurrence-free survival (RFS) did not differ between NAR and AR (3-year RFS: 65.2 % [95 % CI, 55.7-76.2] vs 58.1 % [95 % CI, 49.2-68.5]; p = 0.720). In contrast, among 712 (73.4 %) patients with tumors size ≥4 cm, AR was associated with improved RFS (3-year RFS: 34.7 % [95 % CI, 27.5-43.8] vs 44.9 % [95 % CI, 40.4-50.0]; p = 0.018).
Anatomic resection was associated with improved RFS for ICC patients with tumors size ≥4 cm, indicating that tumor size may be a valuable criterion to determine the extent of liver resection for resectable ICC patients.
肝内胆管癌(ICC)行解剖性切除(AR)与非解剖性切除(NAR)的作用尚未得到充分研究。本研究旨在明确肿瘤大小对ICC患者AR与NAR相对治疗获益的影响。具体而言,该研究旨在确定一个肿瘤大小阈值,以界定何时采用AR而非NAR可能更有助于接受ICC切除术的患者获得更好的生存结局。
从一个国际多机构数据库中识别出接受肝切除术治疗ICC的患者。采用带有交互项的多变量Cox模型评估肿瘤大小与AR对生存影响之间的关系。
在969例患者中,506例(72.9%)接受了AR,而263例(27.1%)接受了NAR。多变量分析显示肿瘤大小与AR之间存在交互作用(风险比[HR],0.94;95%置信区间[CI],0.88 - 1.00;p = 0.045)。交互作用图显示,对于肿瘤大小≥4 cm的患者,AR与更好的结局相关。在257例(26.5%)肿瘤小于4 cm的患者中,NAR与AR的无复发生存期(RFS)无差异(3年RFS:65.2% [95% CI,55.7 - 76.2] 对58.1% [95% CI,49.2 - 68.5];p = 0.720)。相比之下,在712例(73.4%)肿瘤大小≥4 cm的患者中,AR与改善的RFS相关(3年RFS:34.7% [95% CI,27.5 - 43.8] 对44.9% [95% CI,40.4 - 50.0];p = 0.018)。
解剖性切除与肿瘤大小≥4 cm的ICC患者RFS改善相关,这表明肿瘤大小可能是确定可切除ICC患者肝切除范围的一个有价值的标准。